EUVIMEDEUVIMED entdecken
Crossref

Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects

Zhi Cao, Jiahao Zhang, Mengrao Guo, Bin Shao, Xiujian Wei, Sen Li, Peng Wang, Xin Zhai

Bioorganic Chemistry · 2023

DOI: 10.1016/j.bioorg.2023.106563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2023. Verfasst von Zhi Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The exploration of novel anaplastic lymphoma kinase (ALK) and tropomyosin receptor kinase (TRK) dual inhibitors tended to serve as targeted treatment of cancer. Herein, a series of phenyl triazole derivatives were designed and synthesized as ALK/TRK dual regulators based on structure-based drug design (SBDD) strategy and were evaluated for antiproliferative activity by MTT assay. Accordingly, all compounds showed surprising cytotoxicity with IC50 values below 10 μM on KM12, H2228 and KARPAS299 cell lines. Among them, compound 13a bearing (2-(4-methylpiperazin-1-yl)phenyl)morpholinomethanone moiety was identified as the optimal hit in enzymatic screening with IC50 values of 1.9 nM (TRKA), 7.2 nM (ALK) and 65.2 nM (ALKL1196M), respectively. Furthermore, 13a could inhibit KM12 cell migration and colony formation in a dose dependent manner. Meanwhile, AO/EB staining indicated that the pro-apoptotic effect of 13a was comparable to that of Entrectinib at the dose of 200 nM. Ultimately, the binding model of 13a with TRKA and ALK well established its mode of action which accounted for the superior activities as a promising antitumor candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesAntineoplastic AgentsAnaplastic Lymphoma KinaseTriazolesProspective StudiesProtein Kinase InhibitorsProto-Oncogene ProteinsCell Line, TumorCell ProliferationStructure-Activity Relationship

Stichwörter der Autor:innen

ALKAntitumorDual inhibitorPhenyl triazoleTRK

Substanzen

Anaplastic Lymphoma KinaseProtein-Tyrosine KinasesTriazolesProtein Kinase InhibitorsProto-Oncogene ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: zhaixin_syphu@126.com.

Zitieren

APA

Cao, Z., Zhang, J., Guo, M., Shao, B., Wei, X., Li, S., Wang, P., & Zhai, X. (2023). Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106563

Vancouver

Cao Z, Zhang J, Guo M, Shao B, Wei X, Li S, et al. Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects. Bioorganic Chemistry. 2023. doi:10.1016/j.bioorg.2023.106563

BibTeX
@article{Cao2023,
  author = {Cao, Zhi and Zhang, Jiahao and Guo, Mengrao and Shao, Bin and Wei, Xiujian and Li, Sen and Wang, Peng and Zhai, Xin},
  title = {Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects},
  journal = {Bioorganic Chemistry},
  year = {2023},
  doi = {10.1016/j.bioorg.2023.106563}
}
Kostenlos starten →